Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer

Inclusion Criteria: * Postmenopausal women as defined in the protocol page 9; * Histologically and/or cytologically confirmed invasive breast cancer with stage IV disease according to AJCC; * Confirmed ER/PR-positive, and HER-2 negative tumor; * Disease progression on or following prior endocrine therapy with tamoxifen or non-steroidal aromatase inhibitor, as defined in protocol, prior to standard of care (SOC) induction chemotherapy * Patient with documented evidence of visceral disease (including but not limited to hepatic involvement and pulmonary lymphangitic spread of tumor) with sign(s) and/or symptom(s) prior to SOC induction chemotherapy should achieve disease stabilization after the SOC induction chemotherapy, confirmed upon 2 consecutive routine tumor assessments; * ECOG performance status ≤ 2 or Karnofsky performance status ≥ 50% prior to the start of study treatment; * Adequate organ function prior to the start of study treatment as defined in the protocol; * Able to swallow and retain oral medication; * Able to give written informed consent; Exclusion Criteria: * Male patient; * Metastatic disease limited to the bone or soft tissues only and with no history of other visceral metastases; * History of brain or other CNS metastases; * Previous treatment with exemestane, unless exemestane was administered in the adjuvant setting and stopped \>1 year before metastatic relapse; * Untreated with SOC chemotherapy for invasive breast cancer with stage IV disease according to AJCC - or - treated with SOC chemotherapy for invasive breast cancer with stage IV disease according to AJCC without clinical benefit; * History of neurological or psychiatric disorders; * Any serious cardiovascular diseases in the previous 6 months; * Impairment of gastrointestinal function or gastrointestinal disease; * Patients with uncontrolled infection; * Patients with an active, bleeding diathesis or on oral anti-vitamin K medication (except low dose coumadin defined as 1 mg a day); * Chronic treatment with systemic steroids or another immunosuppressive agent; * Patients with a pre-existing peripheral neuropathy \> grade 1; * Patients who are hepatitis B and/or hepatitis C carriers; * Known human immunodeficiency virus infection; * Prior exposure to mTOR inhibitors; * Hypersensitivity to rapamycin or other similar compounds; * Patients taking medications known to be inhibitors or inducers of CYP3A4 and/or PgP will not be included in this study; * Prior treatment with any investigational agent within the preceding 4 weeks; * Other conditions in the judgment of the investigator, would make the patient inappropriate for entry into this study. Other protocol-defined inclusion/exclusion criteria may apply.